| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95%... |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates August 11, 2026 at 7:00 AM EDT Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an incre... |
| 03 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors August 3, 2026 at 7:13 AM EDT Company reports preliminary Q2 2026 AUCATZYL net ... |
| 03 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
Other Equity Interests owned or held by the Issuer or its Subsidiaries |
| 29 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 29, 2026, Autolus Therapeutics plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”). The shareholders considered the six resolutions set forth below, each of which were voted on and duly passed on ... |
| 09 Jun 2026 |
8-K: Other Events
Registered Number 11185179 (England & Wales) Annual Report and financial statements for the year ended 31 December 2025 for Autolus Therapeutics plc |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates May 14, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflectin... |
| 29 Apr 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure
Initiative focused on driving gross profit margin and path to profitability for the ALL business |
| 16 Apr 2026 |
8-K: Changes in Registrant's Certifying Accountant
The UK Firm Ernst & Young LLP is a limited liability partnership registered in England and Wales with registered number OC300001 and is a member firm of Ernst & Young Global Limited. A list of members’ names is available for inspection a... |
| 08 Apr 2026 |
8-K: Regulation FD Disclosure
Spotlight on the Acute Lymphoblastic Leukemia (ALL) Business AUTOLUS INVESTOR EVENT April 8, 2026 EX-99.1 |
| 27 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates March 27, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 ... |
| 26 Jan 2026 |
8-K: Entry into a Material Definitive Agreement
On January 21, 2026, Autolus Limited, a wholly owned subsidiary of Autolus Therapeutics plc (the “registrant”, and together with Autolus Limited, the “Company”), entered into a Master Service Agreement with AGC Biologics S.p.A (“AGC”) fo... |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
Developing Next Generation Programmed T Cell Therapies January 2026 Autolus.com For Investor communication only. Not for use in product promotion. EX-99.2 |
| 02 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
1 Autolus Therapeutics Appoints Ryan Richardson to Board of Directors LONDON & Gaithersburg, MD, December 1, 2025 -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing a... |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates November 12, 2025 at 7:00 AM EST Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 autho... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates August 12, 2025 at 7:00 AM EDT Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025 Comp... |
| 27 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 26, 2025, Autolus Therapeutics plc (the “Company”) held its 2025 Annual General Meeting of Shareholders (the “AGM”). The shareholders considered the nine resolutions set forth below, each of which were voted on and duly passed on... |
| 02 Jun 2025 |
8-K: Other Events
1 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, please seek your own independent financial advice from your stockbroker, solicitor, accountant or other appropriate... |
| 30 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates May 8, 2025 at 7:00 AM EDT Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 million U.K. Medicines and Healthcare products Regulatory Age... |
Loading...